Intervention therapies for insulin-dependent diabetes.
Treatment of insulin-dependent diabetes remains problematic since there continues to be high rates of morbidity and mortality among affected patients. Good outcomes are most likely to be more common among patients who maintain endogenous insulin reserves for the longest time following diagnosis. The disease process can now be identified in its early, pre-symptomatic stages and thus, the time has come for the investigation of preventive therapies through multicenter clinical trials. A wide variety of strategies are available and their choice should be dependent on the pathogenic stage of disease at which treatment is initiated. This stage-specific approach to prevention is discussed with a particular focus on those therapies that will soon be tested in clinical trials.
Muir
A
A
Department of Pediatrics, University of Florida College of Medicine, Gainesville 32610.
Schatz
D A
DA
Pozzilli
P
P
MacLaren
N K
NK
D000818:Animals; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D004353:Drug Evaluation, Preclinical; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D007328:Insulin / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000473:pathology; D008297:Male; D051379:Mice; D016688:Mice, Inbred NOD; D015337:Multicenter Studies as Topic; D011828:Radiation Chimera; D051381:Rats; D011913:Rats, Inbred BB; D012107:Research Design; D012307:Risk Factors; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000473:pathology
D001324:Autoantigens; D007166:Immunosuppressive Agents; D007328:Insulin